Daiichi Sankyo and Merck Receives FDA’s Priority Review for Ifinatamab Deruxtecan (I-DXd) to Treat ES-SCLC

Why It Matters

The priority review accelerates potential U.S. availability of a novel ADC for a disease with few effective post‑platinum options, promising a new revenue stream for both partners and expanding therapeutic choices for ES‑SCLC patients.

Key Takeaways

• FDA grants priority review for I‑DXd in ES‑SCLC
• BLA based on Phase II IDeate‑Lung01 trial (187 patients)
• Study showed objective response at 12 mg/kg dose
• I‑DXd received Breakthrough Therapy Designation in Aug 2025
• Partnership leverages Daiichi Sankyo’s ADC platform with Merck’s commercialization

Pulse Analysis

Extensive‑stage small‑cell lung cancer remains one of the most aggressive thoracic malignancies, with median survival under a year after platinum‑based chemotherapy fails. Conventional options are limited to re‑treatment with topotecan or clinical trials, leaving a sizable unmet need for targeted agents that can deliver cytotoxic payloads directly to tumor cells while sparing healthy tissue. Antibody‑drug conjugates (ADCs) have emerged as a promising class, and ifinatamab deruxtecan (I‑DXd) joins this wave by linking a tumor‑specific antibody to the potent topoisomerase‑I inhibitor deruxtecan, aiming to improve response rates and durability.

The IDeate‑Lung01 Phase II trial enrolled 187 patients who had progressed after one to three prior lines of therapy. Participants received I‑DXd intravenously every three weeks at either 8 mg/kg or 12 mg/kg. The higher dose yielded an objective response rate exceeding 30%, with a median progression‑free survival of roughly five months—metrics that compare favorably against historical controls. Safety signals were manageable, with the most common adverse events being neutropenia and nausea, aligning with the known class effects of deruxtecan‑based ADCs. These data earned the drug a Breakthrough Therapy Designation in August 2025 and formed the backbone of the FDA‑accepted BLA.

The FDA’s priority review, coupled with the Real‑Time Oncology Review and Project Orbis pathways, compresses the decision timeline to an October 10, 2026 PDUFA date. For Daiichi Sankyo, the deal leverages its ADC expertise, while Merck brings a global commercialization engine and deep oncology market reach. Analysts estimate the U.S. ES‑SCLC market could exceed $1 billion annually, positioning I‑DXd as a potential blockbuster if it clears regulatory hurdles. The collaboration also signals a broader trend of joint ventures accelerating innovative therapies to market, reshaping the competitive landscape against other ADCs and emerging immuno‑oncology combos.